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Abstract
Introduction: From a birth cohort of at-risk Asian infants, we prospectively investigated the role of early onset
allergen sensitization and clinical phenotypes as risk factors for atopic disorders at the age of 5 years.
Methods and materials: The study recruited 253 families with a history of allergic disease in a first degree relative
from an antenatal clinic in Singapore. The children were followed prospectively to assess clinical outcomes and skin
prick test was performed at 2 and 5 years of age.
Results: Allergen sensitization (food and/or house dust mites) alone at 2 years of age was not associated with
increased risk of wheeze and eczema at 5 years. However, the clinical phenotype (eczema and wheeze) with or
without the presence of concomitant allergen sensitization at 2 years increased this risk. For eczema, eczema alone
at year 2 increased the risk of eczema at year 5 (adjOR = 7.1; 95 % CI: 1.8–27.8) and this was further increased by the
presence of allergen sensitization (adjOR = 25.4; 95 % CI: 4.7–138.5) and the concomitant presence of both wheeze
and allergen sensitization (adjOR = 64.9; 95 % CI: 4.7–900.0). For wheeze, wheeze alone at 2 years (adjOR = 4.5; 95 %
CI: 1.4 -14.8), and wheeze with concomitant allergen sensitization and eczema (adjOR = 13.9; 95 % CI: 1.2–168.5)
increased the risk of wheeze at 5 years. The exception was rhinitis, where allergen sensitization alone at 2 years
(adjOR = 5.6; 95 % CI: 1.1–29.2) increased the risk of rhinitis at 5 years. Early onset of eczema at 2 years also
increased the risk of rhinitis (adjOR = 6.8; 95 % CI: 2.0–23.1).
Conclusion: In this Asian birth cohort, the clinical phenotype (eczema and wheeze) with or without concomitant
allergen sensitization in the first 2 years of life were strong predictors of atopic disorders at 5 years.
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Background
Although eczema, wheeze and rhinitis are considered
atopic disorders, their onset in early childhood may
occur in the absence of allergy or allergic sensitization
[1–3]. It is well known that children with atopic disease
often exhibit IgE sensitization [4], but the ability of this
sensitization to predict the subsequent development of
atopic disease is less clear. Thus, there has been consid-
erable interest in understanding the relationship between
early-life atopic manifestations and allergen sensitization
on the outcome of atopic disorders in children. The aim
was to study the relationship of the clinical phenotype
and allergen sensitization in the first 2 years of life on
the manifestations of eczema, wheeze and rhinitis at
5 years of age.
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This study utilized data collected prospectively from a
birth cohort derived from a double-blind, placebo-
controlled randomized study (ClinicalTrials.gov Identifier:
NCT00318695) that was conducted to assess the effect of
probiotic supplementation in the first 6 months of life on
the incidence of allergic diseases. The study recruited 253
families with a history of allergic disease from the ante-
natal clinics at the National University Hospital, Singapore
from May 2004 to June 2006. Details of subject recruit-
ment and clinical assessment have been previously de-
scribed [5]. The primary clinical outcome measure was
the incidence of eczema, and the secondary outcome mea-
sures were wheeze, rhinitis and allergen sensitization.
Analysis at the age of 12 months showed no statistical dif-
ference in eczema, wheeze and allergen sensitization
between the probiotic supplemented group and controls
[5]. Written informed consents were obtained from all
families. The study was approved by the National Univer-
sity Hospital’s ethics review committee (DSRB Ref Code:
B/00/322).
Definition of eczema, wheeze and rhinitis and clinical
follow-up
Infants were evaluated clinically by a paediatrician at 1,
2 and 5 years of age, which involved a detailed history,
recording of anthropometric data and clinical examin-
ation, including looking for the presence of allergic
disorders. Questionnaires (not validated) were also ad-
ministered by the candidate and research nurses at these
visits to record clinical disease and environmental expo-
sures, including day care, sibship, use of antibiotics,
passive smoke and pets. Biweekly phone calls were per-
formed for the first 2 years after which once every three
month phone contacts were done to collect data on the
health status of the children. Eczema was defined as a
pruritic rash over the face and/or extensors with a
chronic relapsing course, as described by Hanifin and
Rajka and modified by Seymour et al. for infants [6].
The Scoring Atopic Dermatitis (SCORAD) index was
used to objectively score the severity of atopic dermatitis
[7]. Recurrent wheeze/asthma was diagnosed if the child
had three episodes of nocturnal cough with sleep distur-
bances or wheezing symptoms, separated by at least
seven days, in a setting where recurrent wheeze/asthma
was likely and conditions other than allergy have been
excluded [8]. The subjects were diagnosed with rhinitis
if the child had rhinorrhea, nasal obstruction, nasal itch-
ing and sneezing which were reversible spontaneously or
with treatment and that was not due to a respiratory in-
fection as per recommendations from the World Health
Organization (WHO) Allergic Rhinitis and its Impact on
Asthma workshop (ARIA) [9].
Skin prick testing
Skin prick test was performed at 2 and 5 years using
standardized technique with common allergen extracts,
including soy (Alyostal, Stallergenes Laboratoires,
France), cow’s milk, egg yolk, egg white, peanuts and
shrimp, house dust mite (HDM) allergens - Dermato-
phagoides pteronyssinus (Greer Laboratories, Lenoir,
NC) and Blomia tropicalis (manufactured in-house) [10].
A wheal size of at least 3 mm in diameter above the
negative control was considered positive [11].
Statistical analysis
Statistical analysis was performed using the SPSS software
version 17.0 for Windows (SPSS, Inc. Chicago III, and
USA). Quartiles and median cut off were generated for
SCORAD scores to study the effect of eczema severity on
clinical outcomes of eczema, wheeze, rhinitis, and allergen
sensitization at 5 years of age. Chi-square analysis was
used to compare univariate relationships between risk fac-
tors and occurrence of eczema, wheeze and rhinitis at
5 years. Logistic regression analyses were used to evaluate
the independent roles of clinical phenotypes or/and aller-
gen sensitization in the first 2 years of life with the clinical
outcomes of eczema, wheeze, rhinitis and allergen
sensitization at 5 years of age. The dependant variable was
eczema, wheeze, rhinitis and allergen sensitization at
5 years and the covariate was a 16 level variable account-
ing for the risk severity of 4 variables (eczema, wheeze,
rhinitis and HDM sensitization in the first 2 years of life).
Confounding variables with a p value <0.1 were included
into the logistic regression model for adjustment. These
factors included: probiotic supplementation, mode of de-
livery, gender, serum total IgE at 1 year, ethnic group, pa-
ternal atopy, maternal atopy and sibling atopy.
Results
There were 253 at risk newborns recruited to this study.
The ethnic distribution was Malay (45.5 %), Chinese
(43.5 %), and others (11.1 %), with 53 % of the cohort
female. At 2 years, 231 (91.3 %) subjects remained in the
study, and 219 (86.5 %) were left at 5 years. There were no
significant differences in demographics between those
who remained in the study and the drop-outs (data not
shown). The prevalence of the eczema, wheeze and rhin-
itis showed varying trends in the first 5 years of life (Fig. 1).
For eczema, the prevalence decreased from 24.7 % (57/
231) to 11.9 % (26/219) at the age of 5 years due to remis-
sion of early onset eczema. Out of the 26 subjects with ec-
zema at year 5, 8 subjects had onset after the age of
2 years. The prevalence of wheeze was relatively stable
throughout at 21.2 % (49/231) at 2 and 15.1 % (33/219) at
5 years, with 30.6 % (15/49) of early onset (<2 years)
wheeze persisting to five years. Out of those with early on-
set wheeze, 25 (51.0 %) had recurrent wheeze. In contrast,
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the trends for rhinitis showed a markedly increase from
2.2 % (5/231)) at year 2 to 15.1 % (33/219) at year 5.
In terms of allergen sensitization, house dust mite
(Dermatophagoides pteronyssinus and Blomia tropicalis)
sensitization was more common than sensitization to
common foods (cow’s milk, egg, soy, shrimp and peanut)
at 2 years old (p < 0.05) (Table 1). Positive skin prick test
responses to house dust mites increased further from
17.0 % (39/229) at year 2 to 50.7 % (111/219) at 5 years.
Sensitization to food allergens at the age of 2 years was
relatively low, with 2.2 % (5/229) sensitized to egg white,
0.4 % (1/229) each to egg yolk, cow’s milk and soy, 1.4 %
(3/222) each to peanut and shrimp allergens. Of those
sensitized to food allergens, only one subject in the co-
hort had clinical allergy to egg. There was no significant
association between eczema severity as measured by
SCORAD in the first 2 years of life and allergen
sensitization at 2 years (Table 2). The prevalence of clin-
ical phenotypes associated with HDM sensitization (at
least one HDM allergen) was comparatively low in early
life but increased considerably at 5 years (Fig. 2). In ec-
zema subjects, HDM sensitization increased from 32.1 %
(18/56) at year 2 to 69.2 % (18/26) at year 5, and simi-
larly in wheeze subjects from 20.8 % (10/48) at year 2 to
78.8 % (26/33) at year 5. The rate of HDM sensitization
was 87.9 % (29/33) in rhinitis subjects at year 5.
Notably, we observed transition from a non-sensitized
phenotype at 2 years to a sensitized phenotype in 8/18
subjects whose eczema persisted to 5 years, and in 10/15
subjects whose wheeze persisted to 5 years.
To examine the role of HDM sensitization and clinical
phenotypes in the first 2 years of life on the development
of eczema, wheeze, rhinitis and allergen sensitization at
year 5, a 16-level variable was formed using these 4 vari-
ables to account for their risk severity by placing all the
combinations of the 4 variables into one 16 level variable
(Table 3). Similar results were also obtained when any
allergen sensitization (both HDM and food) was ana-
lysed (data not shown). We found that having eczema at














































Fig. 1 Prevalence of atopic phenotypes from birth up to 2 years and at 5 years old. Light grey columns represent % of subjects with onset 0–2
years and dark grey columns % of subjects with onset between 2 and 5 years. Prevalence is presented as percentage. The cohort comprises of
231 and 219 subjects at year 2 and 5 respectively
Table 1 Characteristics of Allergen Sensitization at 2 Years and
at 5 Years of Age
2 years old 5 years old
Allergen sensitization (%) n = 229 a n = 219
Food allergen (any) 7 (3.1 %) * N.D.
Cow’s milk 1 (0.4 %)
Egg white 5 (2.2 %)
Egg Yolk 1 (0.4 %)
Soy 1 (0.4 %)
Shrimp 3 (1.4 %) +
Peanut 3 (1.4 %) +
Inhalant allergens (any dust mite) 39 (17.0 %) * 111 (50.7 %)
Dermatophagoides pteronyssinus 37 (16.2 %) 97 (44.3 %)
Blomia tropicalis 11 (4.8 %) 81 (36.5 %)
N.D. not done
a indicates missing SPT data, * indicates statistically significant (p < 0.05), +
indicates n = 222 instead of 229
Table 2 Characteristics of allergen sensitization at 2 years of
age against severity of Eczema up to 2 years
Allergen sensitization
SCORADb (quartile range) Presence Absence Total
Upper quartile (<22.56) 8 5 13
Mid upper quartile (17.11–22.55) 4 10 14
Mid lower quartile (11.075–17.10) 3 10 13
Lower quartile (<11.075) 6 7 13
Total quartile 21 32 53a
aThere were 4 subjects with missing SCORAD data
b Denotes highest SCORAD recorded in the first 2 years of life
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(adjOR = 7.1; 95 % CI = 1.8–27.8). In addition, the pres-
ence of concomitant allergen sensitization alone or aller-
gen sensitization with wheeze further increased the risk
(adjOR = 25.4; 95 % CI = 4.7–138.5, and adjOR = 64.9; 95
% CI = 4.7–900.0, respectively) (Table 3).
For wheeze at 5 years of age, wheeze alone at 2 years
was a risk factor (adjOR = 4.5; 95 % CI = 1.4–14.8)
(Table 3). The concomitant presence of eczema and al-
lergen sensitization (adjOR = 13.9; 95 % CI: 1.2–168.5)
increased the risk of wheeze at 5 years. When wheeze at
2 years were subgrouped into recurrent wheeze and sin-
gle episode wheeze, both groups showed similar risks for
wheeze at 5 years (data not shown).
For rhinitis at 5 years of age, early allergen sensitization
to house dust mites increased the risk of rhinitis at 5 years
(adjOR = 5.6; 1.1–29.2). Early onset of eczema by 2 years
also increased the risk of rhinitis (adjOR = 6.8; 95 % CI =
2.0–23.1).
For HDM allergen sensitization at 5 years of age, aller-
gen sensitization at 2 years was the strongest risk factor
(adjOR = 9.0; 95 % CI = 2.3–35.3), but early onset of
eczema also increased the risk (adjOR = 3.6; 95 % CI =
1.5–8.7).
The effect of eczema severity on atopic outcomes at
5 years was evaluated while adjusting for other variables
using logistic regression. We found that although both
groups (SCORAD above and below median) were sig-
nificantly associated with eczema at 5 years, however,
those with more severe eczema at the age of 2 years
(SCORAD above median for group) was more strongly as-
sociated with eczema at year 5 than those with less severe
eczema (SCORAD below median for group) (SCORAD
above median: adjOR =15.2; 95 % CI = 4.3–53.7; SCORAD
below median: adjOR = 5.7; 95 % CI = 1.4–22.7). Only
those with more severe eczema was significantly asso-
ciated with the development of allergen sensitization
at 5 years (SCORAD above median: adjOR = 2.9; 95 %
CI = 1.0–8.5). Eczema severity at the age of 2 years did
not affect outcomes for wheeze and rhinitis at 5 years
(p > 0.05).
Discussion
This study aimed to look at the role of early onset aller-
gen sensitization and clinical phenotypes of eczema and
wheeze at the age of 2 years as predictors of the atopic
outcomes at the age of 5 years. This Asian at-risk for al-
lergy birth cohort has shown that allergen sensitization
alone at 2 years of life was not a risk factor for eczema
and wheeze at 5 years old. Instead, the clinical pheno-
type alone (ie, eczema and wheeze) were risk factors,
and the concomitant presence of allergen sensitization
further increased this risk. Therefore, early onset eczema
and wheeze before 2 years of age, are more likely to per-
sist till the age of 5 years old. The allergen panel chosen
were common food allergens in our population [12], and
dust mite allergens. House dust mites (Dermatopha-
goides pteronyssinus, Blomia tropicalis) are the most im-























































Fig. 2 Prevalence of house dust mite sensitization in relation to clinical atopic phenotypes at 2 and 5 years old. Light grey columns represent % of
non-atopic phenotype prevalence and dark grey columns represent % of atopic phenotypes prevalence. Prevalence is presented as percentage.
* indicates missing 1 SPT data
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been shown in a population study of atopic teenagers
and young adults, where almost all subjects were found
to be exclusively sensitized to house dust mite allergens
[13]. In a study by Chew et al., similar results were
found in atopic children where >90 % of the subjects
were sensitized to at least one of the 2 dust mites [14].
Other studies had similar observations but mainly with
the eczema phenotype. The German Multicentre Atopy
Study (GMAS) that recruited 1314 infants [15] observed
that children with early onset eczema and concomitant
wheeze were 3 times more likely to have wheeze at
7 years compared to children without early onset eczema
Further, two birth studies from western Sweden as well
as Germany (GMAS) reported early onset eczema as risk
factors for allergic rhinitis in later childhood [16, 17]. In
The Prevention of Allergy among Children in Trondheim
(PACT) study, children with eczema at 2 years were 2
times more likely to develop asthma at 6 years [18]. The
Tuscon Children’s Respiratory Study also found early
onset of eczema in the first year of life was independ-
ently associated with persistent wheezing at 6 years of
life [2]. Similarly, the Dampness in Building and Health
Study that recruited 3124 children aged 1–2 years and
followed them for 5 years reported that children with
early onset eczema had increased odds of developing
asthma and rhinitis [19].
With regards to early wheeze as a risk factor, a birth
cohort study from Stockholm, Sweden involving 3251
Table 3 Clinical phenotypes and allergen sensitization at 2 years as risk factors for atopic outcomes at 5 years
Allergic phenotypes
5 years Phenotype risk factors at 2 years Adjusted OR (95 % CI) **
Eczema No eczema, wheeze, rhinitis and allergen sensitization (n = 110) a 1
n = 26 Allergen sensitization only (n = 16) 4.0 (0.6–27.5)
Eczema only (n = 32) * 7.1 (1.8–27.8)
Wheeze only (n = 32) 0.7 (0.1–7.2)
Eczema and allergen sensitization (n = 12) * 25.4 (4.7–138.5)
Wheeze and allergen sensitization (n = 4) 9.6 (0.6–142.4)
Eczema and wheeze (n = 3) 28.3 (1.0–814.9)
Eczema, wheeze and allergen sensitization (n = 5) * 64.9 (4.7–900.0)
Wheeze No eczema, wheeze, rhinitis and allergen sensitization (n = 110) a 1
n = 32 b Allergen sensitization only (n = 16) 1.9 (0.3–10.4)
Eczema only (n = 32) 1.4 (0.4–5.5)
Wheeze only (n = 32) 4.5 (1.4–14.8)
Eczema and allergen sensitization (n = 12) 3.1 (0.6–15.7)
Wheeze and allergen sensitization (n = 4) 7.8 (0.8–71.2)
Eczema and wheeze (n = 3) 20.9 (0.9–499.6)
Eczema, wheeze and allergen sensitization (n = 5) 13.9 (1.2–168.5)
Eczema, rhinitis and allergen sensitization (n = 2) 16.5 (0.8–360.2)
Rhinitis No eczema, wheeze, rhinitis and allergen sensitization (n = 110) a 1
n = 32 b Allergen sensitization only (n = 16) 5.6 (1.1–29.2)
Eczema only (n = 32) * 6.8 (2.0–23.1)
Wheeze only (n = 32) 1.7 (0.4–7.9)
Eczema and allergen sensitization (n = 12) 3.8 (0.7–20.6)
Eczema, wheeze and allergen sensitization (n = 5) 10.1 (1.0–104.1)
Allergen sensitization No eczema, wheeze, rhinitis and allergen sensitization (n = 110) a
n = 111 Allergen sensitization only (n = 16) * 9.0 (2.3–35.3)
Eczema only (n = 32) * 3.6 (1.5–8.7)
Wheeze only (n = 32) 1.1 (0.4–2.7)
Statistically significant variables (p < 0.05) highlighted in bold and (p < 0.01) variables highlighted in bold and marked with *
** indicates adjusted for other variables (such as probiotic supplementation, gender, ethnic group, mode of delivery, maternal atopy, paternal atopy, sibling atopy
and IgE measurements at 1 year) in the table that were selected based on the univariate analysis and a p value of <0.1
a indicates the reference group
b indicates missing SPT
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children reported that children who wheezed in the first
2 years of life were 4 times more likely to develop
asthma at 8 years of age compared to the non-wheezers
[20]. In addition, recurrent wheeze of more than 3 epi-
sodes in the first 2 years of life conferred additional risk
to the development of asthma at the age of 8 years [20].
Similarly, the Tuscon Children’s respiratory study re-
ported that persistent wheezing before the age of 3 years
was independently associated with asthma at the age of
22 years [21]. Taken together, these observations indicate
that the clinical phenotype even without allergen
sensitization are risk factors for atopic disorders in later
childhood, and suggests that factors other than allergy
play a role in the development of allergic disorders. This
postulate is substantiated by the large European popula-
tion based cohort study, MeDALL (Mechanisms of the
Development of ALLergy), which showed that eczema,
rhinitis and asthma may coexist in the absence of IgE
sensitization, and that IgE sensitization was not the
dominant causal mechanism of comorbidity for these
disorders ([22]).
We also observed that the clinical phenotype may pre-
cede the development of allergen sensitization in some
subjects with eczema and wheeze. This is similar to a
prospective Thai study which showed that children with
non-allergic rhinitis could develop allergic rhinitis with
subsequent follow up [23]. Further, the Melbourne
Atopy Cohort Study in Australia also showed that chil-
dren with eczema in early life were more likely to have
new allergen sensitization at 1 year and 2 years [24]. We
observed that the severity of eczema in the first 2 years
was associated with eczema and allergen sensitization
at 5 years of age. Similarly, the Consortium of Food
Allergy Research Observational Study reported that
children with history of atopic dermatitis had higher
peanut sensitization when exposed to peanut and the
sensitization rates was further increased in those with
severe atopic dermatitis [25, 26]. Other studies reported
the association between eczema severity and asthma
[29, 30], which we did not observe in our cohort.
Although allergen sensitization may not be the domin-
ant factor in the development of eczema and wheeze in
later childhood, allergen sensitization did play a role. We
observed that early onset allergen sensitization in the
presence of the clinical phenotype was a cofactor in in-
creasing the risk of subsequent atopic disease. Other
studies have made similar observations. The importance
of HDM in increasing the odds of development of atopic
outcomes in the presence of eczema was also reported
by the German Infant Nutritional Intervention (GINI)
Study [31, 32]. This study showed that early HDM
sensitization was a risk factor for eczema at age 6 years
but only if the children already had eczema within the
first 12 months [32]. In the German Multicenter Atopy
Study (GMAS) birth cohort study, children with eczema,
concomitant wheeze and allergen sensitization had
higher risk for the development of wheeze at 7 years
compared to just eczema and wheeze alone [15]. In an-
other cohort of at-risk children from Western Australia,
infants that wheezed and were sensitized to allergens in
the first year of life had the highest rates of subsequent
asthma development [33].
The importance of allergen (HDM sensitization) as an
independent risk factor of subsequent atopy, was only
seen with rhinitis in our Singapore cohort. Similar to
our observations where HDM sensitization was associ-
ated with the subsequent development of rhinitis, the
GINI study has showed that sensitization to aeroallergen
was an independent risk factor for the development of
rhinitis at 6 years of age [32]. In contrast to our findings,
other studies have also shown that aeroallergen
sensitization is an independent risk factor for subsequent
asthma. The Tucson epidemiological study of airways
obstructive disease also found that those with early
sensitization to any aeroallergen before the age of 8 years
were more likely to develop wheeze after the age of 8
[34]. In addition, the Melbourne Atopy Cohort Study in
Australia also showed that house dust mite sensitization
at the age of 1 and 2 years was associated with increased
odds of development of wheeze at 12 years [35].
Of interest are the observations that eczema without
allergen sensitization at the age of 2 years was a risk fac-
tor for allergen sensitization at the age of 5 years, indi-
cating that the eczema phenotype may precede and
predispose to aeroallergen sensitization. This is in sup-
port of the notion that eczema increases the risk of aller-
gen sensitization possibly directly through the inflamed
skin and predisposes to food allergy ([25]). Eczema
therefore appears to be the first manifestation of atopy
as defined by the atopic march. Other studies have re-
ported similar observations. A Swedish study that re-
cruited 94 children with eczema and followed them till
7 years of age found that early onset eczema increased the
odds of subsequent development of allergen sensitization
[26]. Similarly, early onset persistent eczema was signifi-
cantly associated with allergen sensitization at 7 years in a
high risk cohort of 373 Canadian infants [36]. In addition,
a birth cohort study conducted in Isle of Wright that
followed 1218 children till the age of 4 years reported that
eczema in the first 2 years of life was a strong predictor
for aeroallergen sensitization at 4 years [37].
These findings from cohort studies including ours
support the concept of the atopic march where eczema
in early life predisposes to allergen sensitization and
atopic disorders in later childhood [38, 39]. Further, the
airway inflammation associated with early viral wheeze
has been postulated to play a role in subsequent asthma
development [40].
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The limitations of our study are that due to the small
number of subjects with the exposure and outcomes, the
confidence intervals are wide and this also reduces our
statistical power to determine relationships. In addition,
it is possible that wheeze at 5 years of age may not
equate to persistent childhood asthma in all subjects. A
longer follow up will be necessary to determine this.
However, this study has documented these risk factors
for a birth cohort living in the tropics. We have also
documented that clinical phenotype may precede aller-
gen sensitization.
In conclusion, although a relatively small birth cohort,
our data supports the notion that both early manifesta-
tions of the clinical phenotype with or without concomi-
tant allergen sensitization are risk factors for subsequent
atopic disorders, and that the early clinical phenotypes
may precede the allergen sensitization and atopic disease
later in life.
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